The Wall Street Journal recently reported on the new class of anticoagulants currently under development that promise to prevent blood clots without putting patients at risk of bleeding.
“At least a half-dozen experimental blood thinners are in development that inhibit a protein called factor XI, one of several blood factors that regulate how the body forms clots,” the article says.
While the research sounds promising, it may take some time before these drugs are readily available. Clinical trials that are now underway will answer important questions about clinical effectiveness and economic potential of the new drugs. Success in these trials could revolutionize the management of VTE by offering safer and more effective alternatives to existing medications.
#stoptheclot #bloodthinners #anticoagulanttherapy